JP2010504931A - 指向性の使用 - Google Patents
指向性の使用 Download PDFInfo
- Publication number
- JP2010504931A JP2010504931A JP2009529608A JP2009529608A JP2010504931A JP 2010504931 A JP2010504931 A JP 2010504931A JP 2009529608 A JP2009529608 A JP 2009529608A JP 2009529608 A JP2009529608 A JP 2009529608A JP 2010504931 A JP2010504931 A JP 2010504931A
- Authority
- JP
- Japan
- Prior art keywords
- liquid
- active substance
- nicotine
- max
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 claims abstract description 102
- 239000013543 active substance Substances 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 68
- 210000000214 mouth Anatomy 0.000 claims abstract description 43
- 210000005179 oral vestibule Anatomy 0.000 claims abstract description 40
- 239000007921 spray Substances 0.000 claims abstract description 37
- 238000010521 absorption reaction Methods 0.000 claims abstract description 18
- 230000009471 action Effects 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 92
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 91
- 229960002715 nicotine Drugs 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 77
- 238000005507 spraying Methods 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 229920002678 cellulose Chemical class 0.000 claims description 20
- 239000001913 cellulose Chemical class 0.000 claims description 20
- 235000010980 cellulose Nutrition 0.000 claims description 19
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 230000000873 masking effect Effects 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- RFEJUZJILGIRHQ-OMDKHLBYSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-OMDKHLBYSA-N 0.000 claims description 2
- AIBWPBUAKCMKNS-PPHPATTJSA-N 2-hydroxybenzoic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)C1=CC=CC=C1O.CN1CCC[C@H]1C1=CC=CN=C1 AIBWPBUAKCMKNS-PPHPATTJSA-N 0.000 claims description 2
- MQWJVKLIBZWVEL-XRIOVQLTSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.CN1CCC[C@H]1C1=CC=CN=C1 MQWJVKLIBZWVEL-XRIOVQLTSA-N 0.000 claims description 2
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 claims description 2
- YHBIGBYIUMCLJS-UHFFFAOYSA-N 5-fluoro-1,3-benzothiazol-2-amine Chemical compound FC1=CC=C2SC(N)=NC2=C1 YHBIGBYIUMCLJS-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- FGAFEHZTRRYNDF-UHFFFAOYSA-L zinc;3-(1-methylpyrrolidin-2-yl)pyridine;dichloride Chemical compound [Cl-].[Cl-].[Zn+2].CN1CCCC1C1=CC=CN=C1 FGAFEHZTRRYNDF-UHFFFAOYSA-L 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940041678 oral spray Drugs 0.000 description 11
- 239000000668 oral spray Substances 0.000 description 11
- 239000007937 lozenge Substances 0.000 description 10
- 230000000391 smoking effect Effects 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 235000019477 peppermint oil Nutrition 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000004195 gingiva Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000008122 artificial sweetener Substances 0.000 description 3
- 235000021311 artificial sweeteners Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- -1 glycinates Chemical class 0.000 description 3
- 210000000088 lip Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001478778 Cladophora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- MOJARLNQAUEVTG-UHFFFAOYSA-N O.Cl.[Zn].CN1CCCC1C1=CC=CN=C1 Chemical compound O.Cl.[Zn].CN1CCCC1C1=CC=CN=C1 MOJARLNQAUEVTG-UHFFFAOYSA-N 0.000 description 1
- 241001610364 Ovula Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002643 mouth floor Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960001698 nicotine polacrilex Drugs 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940095708 oral spray product Drugs 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200601246 | 2006-09-27 | ||
| US95161907P | 2007-07-24 | 2007-07-24 | |
| PCT/EP2007/008420 WO2008037470A1 (en) | 2006-09-27 | 2007-09-27 | Directional use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232105A Division JP2014076370A (ja) | 2006-09-27 | 2013-11-08 | 指向性の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504931A true JP2010504931A (ja) | 2010-02-18 |
| JP2010504931A5 JP2010504931A5 (https=) | 2010-11-11 |
Family
ID=38776389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529608A Pending JP2010504931A (ja) | 2006-09-27 | 2007-09-27 | 指向性の使用 |
| JP2013232105A Pending JP2014076370A (ja) | 2006-09-27 | 2013-11-08 | 指向性の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232105A Pending JP2014076370A (ja) | 2006-09-27 | 2013-11-08 | 指向性の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10092715B2 (https=) |
| EP (1) | EP2068982A1 (https=) |
| JP (2) | JP2010504931A (https=) |
| KR (1) | KR20090055606A (https=) |
| CN (1) | CN101516426A (https=) |
| AU (1) | AU2007302256A1 (https=) |
| BR (1) | BRPI0716995A2 (https=) |
| CA (1) | CA2660362C (https=) |
| IL (1) | IL197573A0 (https=) |
| MX (1) | MX2009001865A (https=) |
| NO (1) | NO20091345L (https=) |
| RU (1) | RU2009115720A (https=) |
| WO (1) | WO2008037470A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012517337A (ja) * | 2009-02-09 | 2012-08-02 | スウェツリー・テクノロジーズ・アクチボラゲット | ポリマーシェル |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT507187B1 (de) * | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| PL2753202T3 (pl) | 2011-09-06 | 2016-11-30 | Podgrzewanie materiału przeznaczonego do palenia | |
| EP3892125A3 (en) | 2011-09-06 | 2022-01-05 | Nicoventures Trading Limited | Heating smokable material |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| USD701599S1 (en) * | 2013-03-26 | 2014-03-25 | Pediatric Innovations USA, LLC | Nasal device |
| USD732658S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Nasal device with airplane wings |
| USD732659S1 (en) | 2013-03-26 | 2015-06-23 | Pediatric Innovations USA, LLC | Car-shaped nasal device |
| USD701956S1 (en) * | 2013-03-26 | 2014-04-01 | Pediatric Innovations USA, LLC | Nasal device |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| GB201516729D0 (en) * | 2015-09-22 | 2015-11-04 | The Technology Partnership Plc | Liquid nicotine formulation |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| US10532046B2 (en) | 2015-12-03 | 2020-01-14 | Niconovum Usa, Inc. | Multi-phase delivery compositions and products incorporating such compositions |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| US11744964B2 (en) | 2016-04-27 | 2023-09-05 | Nicoventures Trading Limited | Electronic aerosol provision system and vaporizer therefor |
| WO2018113916A1 (en) * | 2016-12-20 | 2018-06-28 | Fertin Pharma A/S | A mucoadhesive oromucosal formulation comprising a nicotine complex |
| CA3085065C (en) | 2017-12-08 | 2023-12-05 | Fertin Pharma A/S | Formulations providing high nicotine concentrations |
| CA3085064C (en) * | 2017-12-08 | 2023-10-24 | Fertin Pharma A/S | Nicotine mouth spray |
| WO2019110072A1 (en) | 2017-12-08 | 2019-06-13 | Fertin Pharma A/S | Nicotine tablet |
| CN112384504A (zh) | 2018-06-15 | 2021-02-19 | R.J.雷诺兹烟草公司 | 烟碱的纯化 |
| JP6676805B2 (ja) * | 2018-07-12 | 2020-04-08 | 株式会社 東亜産業 | 芳香カートリッジ用充填物、それを有する芳香カートリッジ用エアロゾル形成基材およびそれを有する芳香カートリッジ |
| JP7528084B2 (ja) * | 2018-12-28 | 2024-08-05 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | 金属塩を含むニコチン製剤 |
| WO2020235112A1 (ja) | 2019-05-21 | 2020-11-26 | 株式会社 東亜産業 | 被加熱芳香発生体及び芳香カートリッジ、並びに、被加熱芳香発生体の製造方法及び製造装置 |
| US12213510B2 (en) | 2019-09-11 | 2025-02-04 | Nicoventures Trading Limited | Pouched products with enhanced flavor stability |
| US12342847B2 (en) | 2019-09-11 | 2025-07-01 | Nicoventures Trading Limited | Oral product with cellulosic flavor stabilizer |
| CN110558605B (zh) * | 2019-09-27 | 2021-07-06 | 深圳雾芯科技有限公司 | 电子烟液 |
| US12433321B2 (en) | 2019-12-09 | 2025-10-07 | Nicoventures Trading Limited | Oral composition with beet material |
| US12439952B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Moist oral compositions |
| US12599160B2 (en) | 2019-12-09 | 2026-04-14 | Nicoventures Trading Limited | Lipid-containing oral composition |
| US12137723B2 (en) | 2019-12-09 | 2024-11-12 | Nicoventures Trading Limited | Oral products with active ingredient combinations |
| US12310959B2 (en) | 2019-12-09 | 2025-05-27 | Nicoventures Trading Limited | Oral compositions with reduced water content |
| US12439949B2 (en) | 2019-12-09 | 2025-10-14 | Nicoventures Trading Limited | Oral compositions with reduced water activity |
| US12520867B2 (en) | 2019-12-09 | 2026-01-13 | Nicoventures Trading Limited | Buffered oral compositions |
| US12171872B2 (en) | 2019-12-09 | 2024-12-24 | Nicoventures Trading Limited | Oral compositions and methods of manufacture |
| US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
| EP4072338A1 (en) | 2019-12-09 | 2022-10-19 | Nicoventures Trading Limited | Agents for oral composition |
| US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
| US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
| US12151023B2 (en) | 2019-12-09 | 2024-11-26 | Nicoventures Trading Limited | Oral composition with beet material |
| US12550928B2 (en) | 2019-12-09 | 2026-02-17 | Nicoventures Trading Limited | Liquid oral composition |
| US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
| US12491250B2 (en) | 2019-12-09 | 2025-12-09 | Nicoventures Trading Limited | Oral composition with nanocrystalline cellulose |
| US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
| US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
| US11883527B2 (en) | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
| US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
| JP2023504756A (ja) | 2019-12-09 | 2023-02-06 | ニコベンチャーズ トレーディング リミテッド | カンナビノイドを含む口腔用製品 |
| CA3181912A1 (en) | 2020-06-08 | 2021-12-16 | Anthony Richard Gerardi | Effervescent oral composition comprising an active ingredient |
| US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
| WO2022261552A1 (en) * | 2021-06-11 | 2022-12-15 | Boa Nutrition, Inc. | Nozzle with fan for delivering aerosols |
| MX2023015529A (es) | 2021-06-25 | 2024-03-05 | Nicoventures Trading Ltd | Productos orales y metodo de fabricacion. |
| JP2024530905A (ja) | 2021-07-30 | 2024-08-27 | ニコベンチャーズ トレーディング リミテッド | 微結晶性セルロースを含むエアロゾル生成基材 |
| CA3233375A1 (en) | 2021-09-30 | 2023-04-06 | Michael Zawadzki | Oral product with a basic amine and an ion pairing agent |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526205A (ja) * | 1997-12-19 | 2001-12-18 | オリオン コーポレーション | レボシメンダンの粘膜透過的処方 |
| JP2002503684A (ja) * | 1998-02-20 | 2002-02-05 | キー・フン・ハウ | 口内粘膜の浅い潰瘍の処置用乾燥用量型の抗生物質 |
| JP2005511588A (ja) * | 2001-11-02 | 2005-04-28 | スミスクライン・ビーチャム・コーポレイション | ニコチン渇望の減少または予防に有用な経口放出制御形態 |
| JP2005512943A (ja) * | 2001-02-14 | 2005-05-12 | ジーダブリュー ファーマ リミテッド | 医薬製剤 |
| JP2005518392A (ja) * | 2001-12-27 | 2005-06-23 | ファルマシア・アクチエボラーグ | 口腔内投与のためのニコチンを含む液体医薬製剤 |
| JP2005199066A (ja) * | 2004-01-12 | 2005-07-28 | Hewlett-Packard Development Co Lp | 薬剤の作用速度に基づく薬剤の投与装置および方法 |
| WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| JP2006516567A (ja) * | 2003-01-24 | 2006-07-06 | マグル ホールディング エービー | 経粘膜伝達用組成物材料 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2619718B1 (fr) * | 1987-09-02 | 1991-07-12 | Medibrevex | Nouvelles formes galeniques de beta-2-mimetiques pour administration par voie per- et sublinguale |
| GB8828468D0 (en) | 1988-12-06 | 1989-01-05 | Stoppers Co Ltd | Nicotine containing lozenge |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| IT233948Y1 (it) | 1994-07-20 | 2000-02-16 | Plastiape Spa | Dispositivo erogatore tascabile,particolrmente studiato per immettere nel cavo orale sostanze medicamentose nebulizzate |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| CN1354624A (zh) | 1998-12-15 | 2002-06-19 | Wm·雷格利Jr·公司 | 从口香糖中控制释放活性剂 |
| US6799576B2 (en) * | 1999-07-16 | 2004-10-05 | Aradigm Corporation | System for effecting smoking cessation |
| NZ521034A (en) * | 2000-02-28 | 2004-08-27 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
| SE0003665D0 (sv) * | 2000-10-11 | 2000-10-11 | Astrazeneca Ab | A delivery device |
| SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| PT1578422E (pt) * | 2002-12-20 | 2007-06-14 | Niconovum Ab | Material particulado contendo nicotina fisicamente e quimicamente estável |
| GB0305581D0 (en) | 2003-03-11 | 2003-04-16 | Dallas Burston Ltd | Dispensing devices |
| EP1893953A2 (en) * | 2005-05-18 | 2008-03-05 | The GI Company, Inc | Oral drug delivery system and methods of use thereof |
-
2007
- 2007-09-27 CN CNA2007800361099A patent/CN101516426A/zh active Pending
- 2007-09-27 JP JP2009529608A patent/JP2010504931A/ja active Pending
- 2007-09-27 US US12/440,817 patent/US10092715B2/en active Active
- 2007-09-27 AU AU2007302256A patent/AU2007302256A1/en not_active Abandoned
- 2007-09-27 MX MX2009001865A patent/MX2009001865A/es not_active Application Discontinuation
- 2007-09-27 EP EP07818503A patent/EP2068982A1/en not_active Withdrawn
- 2007-09-27 CA CA2660362A patent/CA2660362C/en active Active
- 2007-09-27 RU RU2009115720/14A patent/RU2009115720A/ru unknown
- 2007-09-27 KR KR1020097006341A patent/KR20090055606A/ko not_active Ceased
- 2007-09-27 WO PCT/EP2007/008420 patent/WO2008037470A1/en not_active Ceased
- 2007-09-27 BR BRPI0716995-7A patent/BRPI0716995A2/pt not_active Application Discontinuation
-
2009
- 2009-03-12 IL IL197573A patent/IL197573A0/en unknown
- 2009-04-01 NO NO20091345A patent/NO20091345L/no not_active Application Discontinuation
-
2013
- 2013-11-08 JP JP2013232105A patent/JP2014076370A/ja active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526205A (ja) * | 1997-12-19 | 2001-12-18 | オリオン コーポレーション | レボシメンダンの粘膜透過的処方 |
| JP2002503684A (ja) * | 1998-02-20 | 2002-02-05 | キー・フン・ハウ | 口内粘膜の浅い潰瘍の処置用乾燥用量型の抗生物質 |
| JP2005512943A (ja) * | 2001-02-14 | 2005-05-12 | ジーダブリュー ファーマ リミテッド | 医薬製剤 |
| JP2005511588A (ja) * | 2001-11-02 | 2005-04-28 | スミスクライン・ビーチャム・コーポレイション | ニコチン渇望の減少または予防に有用な経口放出制御形態 |
| JP2005518392A (ja) * | 2001-12-27 | 2005-06-23 | ファルマシア・アクチエボラーグ | 口腔内投与のためのニコチンを含む液体医薬製剤 |
| JP2006516567A (ja) * | 2003-01-24 | 2006-07-06 | マグル ホールディング エービー | 経粘膜伝達用組成物材料 |
| JP2005199066A (ja) * | 2004-01-12 | 2005-07-28 | Hewlett-Packard Development Co Lp | 薬剤の作用速度に基づく薬剤の投与装置および方法 |
| WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| JP2007533697A (ja) * | 2004-04-22 | 2007-11-22 | デュオコート エービー | グルココルチコイド救急治療用の医薬組成物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012517337A (ja) * | 2009-02-09 | 2012-08-02 | スウェツリー・テクノロジーズ・アクチボラゲット | ポリマーシェル |
| US10099192B2 (en) | 2009-02-09 | 2018-10-16 | Cellutech Ab | Polymer shells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101516426A (zh) | 2009-08-26 |
| MX2009001865A (es) | 2009-04-07 |
| KR20090055606A (ko) | 2009-06-02 |
| AU2007302256A1 (en) | 2008-04-03 |
| CA2660362A1 (en) | 2008-04-03 |
| NO20091345L (no) | 2009-04-01 |
| WO2008037470A1 (en) | 2008-04-03 |
| US10092715B2 (en) | 2018-10-09 |
| RU2009115720A (ru) | 2010-11-10 |
| EP2068982A1 (en) | 2009-06-17 |
| US20100108059A1 (en) | 2010-05-06 |
| IL197573A0 (en) | 2009-12-24 |
| BRPI0716995A2 (pt) | 2013-10-15 |
| JP2014076370A (ja) | 2014-05-01 |
| CA2660362C (en) | 2018-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2660362C (en) | Use of a device or spray apparatus for oral administration of a liquid containing an active substance for improved absorption | |
| RU2279871C2 (ru) | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта | |
| CA2127253C (en) | Composition to help stop smoking | |
| US7767698B2 (en) | Formulation and use thereof | |
| US20090023819A1 (en) | Use of an Artificial Sweetener to Enhance Absorption of Nicotine | |
| US8381739B2 (en) | Systems and methods for effecting cessation of tobacco use | |
| CA2487699C (en) | A buffered, liquid nicotine composition for pulmonary administration | |
| US20080138399A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| US20080138398A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| US20080138294A1 (en) | Systems and methods for effecting cessation of tobacco use | |
| MX2012009586A (es) | Patillas de gelatina blanda con nicotina. | |
| JP2019520361A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
| Chauhan et al. | Nicotine replacement therapy for smoking cessation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100924 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100924 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121011 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130128 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131108 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131203 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140124 |